This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Seattle Genetics Highlights Data From Broad ADCETRIS® (Brentuximab Vedotin) Development Program At ASH 2013

Seattle Genetics, Inc. (Nasdaq: SGEN) today summarized ADCETRIS (brentuximab vedotin) data in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma from multiple presentations at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013. Highlights include encouraging interim data from a phase 2 clinical trial evaluating ADCETRIS as a single-agent for previously untreated HL patients age 60 or older and updated data from a phase 1 clinical trial of ADCETRIS in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma (MTCL) patients, commonly referred to as peripheral T-cell lymphoma (PTCL). In addition, data were presented from an investigator-sponsored phase 2 clinical trial evaluating ADCETRIS in relapsed cutaneous T-cell lymphoma (CTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is currently not approved for the treatment of frontline HL, frontline MTCL or relapsed CTCL.

“ADCETRIS is being evaluated broadly through more than 20 ongoing corporate and investigator-sponsored clinical trials in a variety of Hodgkin lymphoma and non-Hodgkin lymphoma disease settings,” said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. “The interim data evaluating ADCETRIS as a treatment for older Hodgkin lymphoma patients are particularly encouraging, suggesting compelling activity and a manageable safety profile in a patient population that historically cannot tolerate conventional combination chemotherapy regimens and has inferior outcomes. In addition, updated data from trials evaluating ADCETRIS in both frontline mature T-cell lymphoma and cutaneous T-cell lymphoma provide strong rationale for the ongoing phase 3 ECHELON-2 and ALCANZA clinical trials.”

Frontline Data Presentations

A Phase 2 Study of Single-Agent Brentuximab Vedotin for Frontline Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results (Abstract #4389)

Data were presented from an ongoing phase 2 clinical trial evaluating ADCETRIS as frontline therapy for patients age 60 or older with previously untreated HL. The data presented are from a trial that is designed to assess the activity and tolerability of ADCETRIS as a monotherapy for older HL patients who have received no prior treatment. Interim data were reported from 19 patients. The median age of patients was 78 years (range, 64 to 92). The data were highlighted in a poster presentation by Dr. Christopher Yasenchak from the Northwest Cancer Specialists in Tualatin, OR. The key findings included:
  • Of the 19 patients evaluable at the time of this analysis, 17 patients (89 percent) had an objective response, including 12 (63 percent) complete remissions and five (26 percent) partial remissions.
  • All 19 patients (100 percent) achieved tumor reduction as determined by best percentage change from baseline.
  • The median duration of treatment was 18 weeks (six cycles) at the time of analysis.
  • The most common treatment-emergent adverse events were Grade 1 or 2 and included peripheral sensory neuropathy (47 percent), fatigue (32 percent), diarrhea (26 percent), peripheral edema (26 percent), itching (26 percent), hair loss (21 percent), nausea (21 percent) and urinary tract infection (21 percent).
  • Grade 3 events occurring in one patient each included peripheral sensory neuropathy, rash, neutropenia and dizziness upon standing. No Grade 4 events were observed.

Brentuximab Vedotin Administered Before, During, and After Multi-agent Chemotherapy in Patients with Newly-diagnosed CD30+ Mature T- and NK-cell Lymphomas (Abstract #4386)

Data were presented from a phase 1 clinical trial evaluating ADCETRIS administered in combination with or sequentially with chemotherapy for the treatment of newly-diagnosed MTCL. Data were reported in 13 patients who received sequential treatment with two cycles of ADCETRIS followed by six cycles of the combination chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) and 26 patients who received the combination regimen of ADCETRIS plus CHP (A+CHP), which removes vincristine (Oncovin). The median age of patients was 57 years. The data were highlighted in a poster presentation by Dr. Michelle Fanale from The University of Texas MD Anderson Cancer Center.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs